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G protein-dependent and independent signaling pathways perform crucial roles in dopamine-
related physiological and pathological processes. A pivotal role of dopamine in the CNS is the 
control of locomotion; disruption to dopaminergic systems, such as reduced striatal D2 receptor 
availability, contributes to the development of movement disorders. Affected members of a 
family with dystonia, a movement disorder, are heterozygous for a SNP in exon 4 of D2DR 
(c.634A>T p.I212F), a missense variant located within the third intracellular loop; specifically, 
the variation is in the middle of a short stretch of residues that have been found to be critical for 
binding of arrestin and several other dopamine receptor-interacting proteins.  The comparative 
actions between D2-WT and D2-I212F were analyzed in their effects on both the G protein-
mediated pathway and the arrestin3 pathway. It was shown that the D2-I212F variant was only 
34% as effective as D2-WT at recruiting arrestin3, a deficiency that is likely to have important 
behavioral consequences. Additionally, quinpirole stimulation of D2-I212F produced dose-
dependent inhibition of cAMP accumulation; it was observed that lower concentrations of 
quinpirole were able to fully activate the rare variant. To further investigate whether this 
missense variant causes movement disorders, a condition that mimics the heterozygosity (D2-
WT/D2-I212F), for the SNP affected patients have, was utilized and tested. Co-transfection of 
D2-WT and D2-I212F trended toward a shift in the EC50, where D2-WT/D2-I212F were 
different from D2-WT expressed alone, but the difference was not statistically different.  This 
variant is likely to have decreased arrestin-mediated signaling and enhanced G protein-mediated 
signaling, so behaviors and cellular functions mediated by those two pathways will be altered 






adenylyl cyclase (AC ) - bioluminescence resonance energy transfer (BRET) - cyclic adenosine 
monophosphate (cAMP) - CAMYEL (cAMP sensor using YFP-Epac-Rluc) - DMEM 
(Dulbecco’s modified Eagle’s medium ) - dopamine (DA) - D2 dopamine receptor (D2DR) - 
D2L (D2- long) - D2S (D2- short) - Epac (exchange protein directly activated by cAMP) - FBS 
(fetal bovine serum) - green fluorescent protein (GFP) - GRK (G protein coupled receptor 
kinase) - G protein coupled receptors (GPCR) - HD (Huntington’s Disease) - HEK293 (Human 
embryonic kidney 293) - PBS (phosphate buffered saline) - pDNA (plasmid deoxyribonucleic 
acid) - PEI (polyethyleneimine) - Renilla luciferase (Rluc) - SNP (single-nucleotide 
polymorphism) - third intracellular loop (IL3) - transmembrane (TM) - yellow fluorescent 
protein (YFP)  
Introduction: 
1. Dopamine Receptors 
Dopamine (DA) receptors are members of the family of seven-transmembrane (7-TM) 
proteins that interact with distinct signaling molecules on the extracellular domain, inducing 
subsequent changes in the structure of the intercellular domain. 7-TM proteins are the largest 
family of transmembrane protein receptors, most of them signal via heterotrimeric G proteins 
and are therefore called G protein-coupled receptors (GPCRs) (Liu et al., 2007; Pierce and 
Lefkowitz, 2001; Neve, 2010). GPCRs are categorized into three groups, in which dopamine 
receptors are classified within the largest subgroup Class A (Neve, 2010). This subgroup is 
comprised of receptors that respond to biogenic amines, peptides, and odorants. DA receptors 
respond when bound by their endogenous ligand dopamine, a biogenic amine.   
1.1.  Dopamine Receptor Types and Gene Organization  
There are two broad classes of DA receptors, D1- and D2- like DA receptors (Neve, 2010; 
Usiello et al., 2000). Gene organization for either can be divided up into coding and regulatory 
regions; moreover, D1-like receptor genes contain only one exon and no introns, whereas D2-
like receptor genes contain several coding exons positioned in-between introns. The D1-
subfamily comprises the D1 and D5  DA receptors and the D2-subfamily comprises the D2, D3, 
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and D4 DA receptors. D2 dopamine receptors (D2DR) are encoded by genes that contain introns 
and are further divided into respective isoforms (Neve, 2010; Usiello et al., 2000). The 
alternative splicing of an 87-bp exon in the D2 receptor gene results in two transcript variants 
that encode the distinct isoforms D2-short (D2S) and D2-long (D2L) (Usiello et al., 2000). D2L 
has 29 more amino acid residues, in the third intracellular loop (IL3) between TM domains 6-7, 
than D2S as the result of the alternatively spliced exon that is present in the former but spliced 
out of the latter (Usiello et al., 2000). IL3 is involved in the coupling of D2DR to different G 
proteins.  
G proteins are guanine nucleotide binding proteins that bind to and hydrolyze guanosine 
triphosphate (GTP) to guanosine diphosphate (GDP). The heterotrimeric G protein complexes 
are composed of three subunits: alpha, beta, and gamma (Hilger et al., 2018; Tuteja 2009). D1- 
and D2-like receptors couple to different heterotrimeric G-proteins; D1-like receptors signal via 
Gαs and Gαolf whereas D2-like receptors signal via Gαi and Gαo, each activating a unique set of 
signaling pathways (Hilger et al., 2018; Tuteja 2009). 
1.2.  G protein-Coupled Receptor Signaling Pathways 
D2DR is a GPCR that undergoes a conformational change upon activation by a ligand, 
initiating subsequent signaling through G proteins as well as through G protein-independent 
pathways. The former activity is due to the exchange of GDP/ GTP associated with the Gα 
subunit, a function of D2DR as a guanine nucleotide exchange factor (Tuteja 2009). Upon the 
exchange, the Gβ/Gγ dimer dissociates from Gα, allowing each moiety to act upon their 
downstream effectors. One effect of G protein activation by D2DR is the inhibition of adenylyl 
cyclase (AC) activity, which decreases the production of cyclic adenosine monophosphate 
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(cAMP), a second messenger used for intracellular signal transduction in many biological 
processes. Following signal propagation, the GTP associated with the Gα subunit is hydrolyzed 
to GDP, deactivating and subsequently re-associating Gα with the Gβ/Gγ dimer, forming the 
inactive heterotrimeric complex (Tuteja 2009). Signal responses can also be attenuated by the 
phosphorylation of D2DR by G protein coupled receptor kinases (GRKs), allowing for the 
propagation of alternative signaling pathways (Beaulieu et al., 2005).  
Upon activation of D2DR, signaling can be directed toward heterotrimeric G protein- 
independent pathways by means of arrestin3 recruitment. The activated receptor is a substrate for 
GRK 2/3, which phosphorylates serine and threonine residues in IL3 of D2DR. A segment of 
residues, 212-215, in IL3 of D2DR is also required for recruitment of arrestin to the receptor and 
receptor internalization (Lan et al., 2009). In arrestin-dependent receptor internalization, arrestins 
act as adapters for β(2) adaptin and clathrin by bringing activated receptors to clathrin-coated pits 
for endocytosis (DeWire et al., 2007). In addition to the critical roles of arrestin in receptor 
internalization and termination of G protein-dependent signaling, arrestins function as scaffolds 
for signaling proteins. In one such case, a signaling complex is formed in which arrestin3 
mediates the interaction of protein kinase B (Akt) and protein phosphatase 2A in response to 
agonist activation of D2DR (Beaulieu et al., 2005). This signaling mechanism may be involved 
in the expression of locomotive responses to dopaminergic drugs, such as amphetamine and 
apomorphine (Beaulieu et al., 2005). 
 
2. Bioluminescence Resonance Energy Transfer (BRET)  
Bioluminescence resonance energy transfer (BRET) is a transfer of energy between a 
donor enzyme and a fluorophore (acceptor), upon being in close proximity (10–100 Å apart), 
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whereby the enzyme transfers its excited-state energy to the fluorophore, a ground-state acceptor, 
resulting in light emission at a longer wavelength. In nature when the photoprotein aequorin 
transfers energy to green fluorescent protein (GFP), it emits green light as seen in the jellyfish, 
Aequorea victoria; in vitro, purified aequorin emits blue light, a shorter wavelength, in the 
absence of GFP (Xu et al., 1999). This naturally occurring process can be used in the laboratory 
to measure protein interactions in vivo and in vitro. Since the first use of BRET by Xu et al. 
(1999) the technique has been used to study protein-protein interactions well over a thousand 
times, half of which involve GPCR interactions (Pfleger et al., 2006). 
2.1.  BRET Assay to Study Arrestin Recruitment  
Ligand induced recruitment of arrestin by GPCRs, has been dynamically monitored using 
BRET (Donthamsetti et al., 2015; Pfleger et al., 2006; Stoddart et al., 2015). To study arrestin 
recruitment by GPCRs, proteins are modified by means of fusion to accessory protein fragments, 
that act as donor and acceptor. In many of these studies, the GPCRs are fused to a BRET donor 
that are variants of the enzyme Renilla reniformis luciferase (Rluc), whereas the other interacting 
proteins are fused to fluorescent acceptors that are variants of GFP. In our case, D2DR was fused 
to Rluc8, a variant of the luciferase protein (Clayton et al., 2014) and arrestin3 was coupled to a 
yellow fluorescent protein (YFP) called mVenus. The oxidation of the substrate, coelenterazine 
h, upon enzymatic cleavage by Rluc8 produces luminescence that excites the fluorophore 
mVenus, resulting in fluorescence emittance. The intensity of light emissions by Rluc8 and 
mVenus are measured and the ratio is calculated as the BRET signal. The intensity of the BRET 
signal will vary based on the relative distance between Rluc8 and mVenus, indicating arrestin3 
recruitment to D2DR. 
2.2.  CAMYEL Assay to Study cAMP Regulation  
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Ligand induced cAMP regulation by GPCRs has been dynamically monitored using a BRET 
sensor for cAMP, CAMYEL (cAMP sensor using YFP-Epac-Rluc) (Jiang et al., 2007; 
Matthiesen and Nielsen, 2011). CAMYEL is composed of a cAMP binding protein, Epac 
(exchange protein directly activated by cAMP), that contains a cAMP binding domain that serves 
as a molecular switch for detecting intracellular second messenger cAMP levels (Valkovic et al., 
2018). Additionally, Epac in CAMYEL is flanked by a BRET pair: variants of Rluc and GFP. 
When cAMP is absent, Epac assumes a closed conformation such that the energy donor Rluc and 
energy acceptor GFP are in close proximity, producing a higher BRET signal; conversely, Epac 
assumes an open conformation upon binding by cAMP allowing Rluc and GFP to move further 
apart, resulting in a loss of BRET (Salahpour, 2012). In this study, the inhibition of cAMP 
accumulation, by the agonist quinpirole, was measured using CAMYEL. 
Problem and Objective: 
Dopamine plays a critical role in the way our brain controls our movements. Disruption 
to dopaminergic systems is known to play a role in movement disorders. The foremost 
dopaminergic system concerned in motor control arises from the substantia nigra (SN). 
Progressive degeneration of dopaminergic neurons in the nigrostriatal system and subsequent 
loss of dopamine in the striatum are causes of Parkinson’s disease, a neurodegenerative disorder 
affecting the motor system (Lizarraga et al., 2016). Huntington’s Disease (HD), a 
neurodegenerative disorder, is caused by a CAG trinucleotide repeat expansion in the HTT gene. 
HD is characterized by involuntary movement and psychological symptoms, in which 
modifications in dopamine function and neurotransmission play a significant role (Cepeda et al., 
2014). The progression of HD is accompanied by reduction in striatal D1- and D2- receptors; this 
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type of reduction is often associated with movement disorders (Lizarraga et al., 2016). It is 
conceivable that D2 receptor dysfunction may lead to similar movement disorders.  
A neurological disorder with autosomal dominant transmission, that produces impaired 
movement similar to HD, has been identified within a Dutch pedigree. The single-nucleotide 
polymorphism (SNP) associated with this disorder occurs in the coding region of the D2DR 
gene, which encodes the D2 subtype of the dopamine receptor. The missense variant in D2DR 
(c.634A>T p.I212F) is within the IL3 in the middle of a short stretch of residues that have been 
found to be critical for binding of arrestin and several other dopamine receptor-interacting 
proteins, as well as for normal expression and agonist-induced internalization of the D2 receptor. 
Preliminary data from the Neve lab indicate that mutating D2 receptor Ile212 to Phe decreases 
the recruitment of arrestin to the receptor. The major objective of this project is to test the 
hypothesis that the D2DR c.634A>T variant (Phe212) causes movement abnormalities by 
showing that the variant has altered function.  
Materials and Methods: 
Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS; Thermo Fisher 
Scientific, Waltham, MA) at 37°C with 5% CO2.  
1. BRET 
HEK293 cells were co-transfected with plasmids, based on the assay (arrestin3 
recruitment or CAMYEL). Constructs were transiently transfected into HEK293 cells using 
polyethyleneimine (PEI; Polysciences, Inc., Warrington, Pa) at a ratio of 3 μL of PEI (1 μg/μL) 
per 1 μg of plasmid DNA (pDNA) for six hours, after which the medium was replaced with fresh 
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DMEM supplemented with 10% FBS. Forty-eight hours after transfection, cells were treated 
with a trypsin-EDTA solution for disengagement and subsequent harvest from culture plates. 
Cells were then resuspended in BRET assay buffer (PBS with 0.1mM CaCl2, 0.5mM MgCl2 and 
0.2 μM ascorbic acid) and plated at (~100,000 cells in 80μL)/well in 96-well OptiPlates 
(PerkinElmer Life Sciences, Waltman, MA). Plates were incubated at 37°C with 5% CO2 for 1 
hour, followed by the addition of 10μL of agonist, at concentrations ranging between 0.1nM and 
10μM, or vehicle. Additionally, 10μL of coelenterazine h was added giving a final concentration 
of 2μM. Emission of the donor and acceptor was measured ten minutes after the addition of the 
agonist using a VictorTM X Light luminescence reader (PerkinElmer Life Sciences, Waltman, 
MA).  
1.1.  Arrestin3 Recruitment Assay 
HEK293 cells were co-transfected with plasmids containing GRK2 (Clayton et al., 
2014.), the receptors D2-WT or D2-I212F fused to Rluc8 (constructed in the lab), and arrestin3 
fused to mVenus to measure D2DR-mediated arrestin3 recruitment. The agonist added was 
dopamine. The BRET signal was calculated according to the following equation: 
Donor + Acceptor emission at 530nm
Donor + Acceptor emission at 460nm
−
Donor emission at 530nm
Donor emission at 460nm
 
Data were analyzed by nonlinear regression using log[agonist] vs. response(three parameters) in 
Prism (GraphPad, San Diego, CA). The basal response was subtracted from the maximal 
dopamine stimulation response for the maximal arrestin3 recruitment analysis. 
1.2.  CAMYEL Assay 
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HEK293 cells were co-transfected with plasmids containing the receptors D2-WT or D2-
I212F, and a CAMYEL sensor (Jiang et al., 2007) to measure D2DR-mediated inhibition of 
cAMP. The agonist added was quinpirole. Additionally, 10μL of forskolin was added to give a 
final concentration of 10μM. The BRET ratio was calculated by dividing emission at 460 nm by 
the emission at 535 nm. This assay was performed four times, with measurements made by 
quadruplicate or triplicate. Data were analyzed by nonlinear regression using log[inhibitor] vs. 
response(three parameters) and log(inhibitor) vs. normalized response in Prism (GraphPad, San 
Diego, CA). The LogIC50 for each experiment was calculated using the former nonlinear 
regression analysis. Results from four independent experiments were averaged. Significant 
differences between groups were determined using a 2-tailed unpaired t-test. 
Results and Discussion: 
1. Arrestin recruitment by D2-I212F in response to dopamine  
  A BRET assay was utilized to monitor the recruitment of mVenus-arrestin3 to Rluc8-
tagged D2-WT and D2-I212F. The interaction between D2-WT and arrestin3 is indicated by a 
dose-dependent increase in the BRET ratio (Fig. 1A), produced by the activation of the receptor 
by dopamine. The D2-I212F variant was only 34% as effective as D2-WT at recruiting arrestin3 
















Dopamine-induced recruitment of arrestin3 to the receptor was significantly less for the D2-
I212F variant than for D2-WT, with a 66% loss of arrestin3 binding. This result agrees with 
previous findings that demonstrated the necessity of a four-residue segment, residues 212-215 in 
IL3, for recruitment of arrestin3 (Lan et al., 2009). Lan et al. 2009 demonstrated that the 
mutation of residues 212-215 in IL3 resulted in 90% reduction of the wild type receptor to recruit 
arrestin. The mutation of residue 212 in IL3 of the D2-I212F variant and the magnitude of its 
subsequent effect on arrestin3 recruitment, relative to the mutation of residues 212-215, suggests 
that I212 alone is important for this function.  
2. D2-I212F-mediated inhibition of cAMP accumulation 
The inhibition of forskolin-induced cAMP accumulation, by the agonist quinpirole, was 
measured using CAMYEL, a BRET sensor based on the guanine nucleotide exchange factor 
A B 
FIGURE 1. D2-mediated arrestin3 recruitment. A, D2-WT-Rluc8- and D2-I212F-Rluc8-
mediated mVenus-Arr3 recruitment in response to incubation with dopamine at the indicated 
concentrations for 10 min before measuring receptor/arrestin3 BRET. B, maximal mVenus-
Arr3 recruitment by D2-I212F-Rluc8 in response to dopamine stimulation, expressed as a 
percentage of the maximal activation by D2-WT.  
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(GEF) Epac. Quinpirole stimulation of D2-WT and D2-I212F produced dose-dependent 
inhibition of cAMP accumulation; it was observed that lower concentrations of quinpirole were 
able to fully activate the rare variant, as demonstrated in the quinpirole dose-response curve that 











To further investigate whether this missense variant causes movement disorders, a 
condition that mimics the heterozygosity (D2-WT/D2-I212F), for the SNP affected patients 
have, was utilized and tested. Co-transfection of D2-WT and D2-I212F trended toward a shift in 
the EC50, where D2-WT/D2-I212F were different from D2-WT expressed alone, but the 
difference was not statistically different (Table 1).   
 
FIGURE 2. D2-mediated inhibition of cAMP accumulation. HEK293 cells were transfected 
with D2-WT, D2-I212F, or D2(WT/I212F) and CAMYEL, a BRET-based cAMP sensor. The 
inhibition of forskolin (10 μM)-stimulated cAMP by quinpirole at the indicated concentrations 
was measured after 10 min. Dose-response curves are representative of four independent 
experiments performed with triplicate or quadruplicate samples (mean ± S.E.). In panel A the 
results are expressed as a percentage of maximum cAMP production by D2-WT, and in panel B 











The variant D2-I212F demonstrated its enhanced ability to activate heterotrimeric G proteins, 
as determined by measuring the inhibition of cAMP accumulation. Additional BRET-based G 
protein activation assays were performed in the Neve lab, using the same plasmids, and 
generated results in agreement with the results reported here. Additionally, subsequent 
experiments in the Neve lab demonstrated that co-transfection of D2-WT and D2-I212F trended 
toward a shift in the EC50 that was significantly different from D2-WT expressed alone.  
Implications and Future Direction:  
The missense variant in D2DR (c.634A>T p.I212F) is likely to be a very rare mutation, but 
it’s important to consider whether the other dozens of D2DR SNPs have similar effects on 
receptor function. Altered D2DR signaling is implicated in brain disorders such as schizophrenia 
and drug addiction. D2DR is one of the most studied markers of susceptibility for schizophrenia; 
strong associations between schizophrenia and several polymorphisms within D2DR have been 
reported. SNPs in D2DR have been shown to influence substance dependence including alcohol 
and opioid addiction. The results from this study suggest that the missense variant in D2DR 
Table 1. Inhibition of cAMP accumulation mediated by D2 receptor in Response to 
Quinpirole The LogIC
50
 values represent the average of four independent experiments 
illustrated in Figure 2. t-test: p<0.05 for D2-WT vs D2-I212F; p<0.05 for D2-I212F vs 
D2(WT/I212F); no significant difference was found between D2-WT and D2(WT/I212F). 
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(c.634A>T p.I212F) is likely to have decreased arrestin-mediated signaling and enhanced G 
protein-mediated signaling, so behaviors and cellular functions mediated by those two pathways 
will be altered according to patients with this variant. The next step for this research is to 
characterize D2-I212F in vivo. The Neve lab is working on producing a mouse model of this 
genetic disease, which will both confirm that this variant is pathogenic and also make it possible 
to identify drugs to treat the disorder. 
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